Daymark Wealth Partners LLC Buys 961 Shares of Boston Scientific Corporation $BSX

Daymark Wealth Partners LLC boosted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 24.9% during the second quarter, Holdings Channel.com reports. The fund owned 4,820 shares of the medical equipment provider’s stock after acquiring an additional 961 shares during the period. Daymark Wealth Partners LLC’s holdings in Boston Scientific were worth $518,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in BSX. Brighton Jones LLC lifted its holdings in shares of Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after acquiring an additional 226 shares during the period. Cidel Asset Management Inc. bought a new position in shares of Boston Scientific in the 1st quarter valued at $219,000. DAVENPORT & Co LLC increased its stake in shares of Boston Scientific by 15.5% in the 1st quarter. DAVENPORT & Co LLC now owns 13,657 shares of the medical equipment provider’s stock valued at $1,378,000 after purchasing an additional 1,828 shares during the last quarter. Kanawha Capital Management LLC bought a new position in shares of Boston Scientific in the 1st quarter valued at $210,000. Finally, Arlington Trust Co LLC increased its stake in shares of Boston Scientific by 638.5% in the 1st quarter. Arlington Trust Co LLC now owns 960 shares of the medical equipment provider’s stock valued at $97,000 after purchasing an additional 830 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

BSX has been the topic of several recent analyst reports. Erste Group Bank lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. Jefferies Financial Group reiterated a “hold” rating on shares of Boston Scientific in a research note on Monday, July 21st. Truist Financial lifted their price target on Boston Scientific from $129.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. BTIG Research reiterated a “buy” rating and issued a $132.00 price target on shares of Boston Scientific in a research note on Wednesday, October 22nd. Finally, Barclays lifted their price target on Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research note on Thursday, October 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Buy” and a consensus price target of $123.77.

Insider Activity

In other Boston Scientific news, Director Ellen M. Zane sold 9,990 shares of Boston Scientific stock in a transaction dated Monday, October 27th. The stock was sold at an average price of $101.13, for a total transaction of $1,010,288.70. Following the transaction, the director directly owned 27,035 shares of the company’s stock, valued at approximately $2,734,049.55. The trade was a 26.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total value of $4,923,500.00. Following the transaction, the executive vice president directly owned 178,342 shares in the company, valued at $17,561,336.74. The trade was a 21.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 112,891 shares of company stock worth $11,501,887 over the last ninety days. Company insiders own 0.50% of the company’s stock.

Boston Scientific Trading Up 0.2%

Shares of NYSE BSX opened at $100.55 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific Corporation has a 52-week low of $83.38 and a 52-week high of $109.50. The firm has a 50 day moving average price of $100.87 and a two-hundred day moving average price of $102.25. The stock has a market cap of $148.98 billion, a P/E ratio of 53.77, a price-to-earnings-growth ratio of 2.02 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The firm had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. During the same period in the prior year, the company posted $0.63 EPS. The company’s revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.